# Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

> **NCT00824382** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 328 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BI 1744 CL 2 µg
- **DRUG:** BI 1744 CL 5 µg
- **DRUG:** BI 1744 CL 10 µg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00824382
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-03
- **Final completion:** —
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824382, "Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00824382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*